Mergers & Acquisitions
By The Online Investor Staff, updated Thu., Mar. 4, 1:31 PM
| This Slide: #73 of 100 |
Slide #73. Beam Therapeutics Inc. — Guide Therapeutics, Inc.
Acquirer:
Beam Therapeutics Inc. (NASDAQ:BEAM)
Acquiree:
Guide Therapeutics, Inc.
Details:
Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced it has completed the acquisition of Guide Therapeutics, Inc. ("GuideTx"), a developer of nonviral drug delivery vehicles for genetic medicines, further expanding the potential reach of Beam's genetic medicines into new target tissues and diseases.
Beam Therapeutics is a biotechnology company. Co. is engaged in creating a class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing life-long cures to patients suffering from serious diseases. Co.'s base editors have two principal components that are fused together to form a single protein: a CRISPR protein, bound to a guide RNA, that utilizes the DNA-targeting ability of CRISPR, but modified to not cause a double-stranded break; and a base editing enzyme, such as a deaminase, which carries out the desired chemical modification of the target DNA base.
BEAM SEC Filing Email Alerts Service
Open the BEAM Page at The Online Investor »
|
|||||||||||||||||||||
Open the BEAM Page at The Online Investor (in a new window) »
|
|
Avg. Broker Rec.
 
|
Buy (3.14 out of 4) 38th percentile
(ranked lower than approx. 62% of all stocks covered)
Analysts' Target Price: BEAM Stock Forecast Based on Zacks ABR data; powered by Xignite |
